Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Account Payables (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Change in Account Payables data on record, last reported at $26.0 million in Q4 2025.

  • For Q4 2025, Change in Account Payables changed N/A year-over-year to $26.0 million; the TTM value through Dec 2025 reached $28.0 million, changed N/A, while the annual FY2025 figure was $24.0 million, 700.0% up from the prior year.
  • Change in Account Payables reached $26.0 million in Q4 2025 per RCUS's latest filing, up from $12.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $26.0 million in Q4 2025 and bottomed at -$19.0 million in Q2 2023.
  • Average Change in Account Payables over 5 years is $1.7 million, with a median of $3.0 million recorded in 2025.
  • Peak YoY movement for Change in Account Payables: surged 1786.79% in 2022, then tumbled 575.0% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $424000.0 in 2021, then soared by 1786.79% to $8.0 million in 2022, then tumbled by 75.0% to $2.0 million in 2023, then tumbled by 750.0% to -$13.0 million in 2024, then surged by 300.0% to $26.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $26.0 million in Q4 2025, $12.0 million in Q2 2025, and $3.0 million in Q1 2025.